Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib in Systemic Lupus Erythematosus
NCT02537028Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of evobrutinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by EMD Serono. Primary endpoints: Treatment Emergent Adverse Events at 4 weeks, Treatment Emergent Adverse Events by Severity at 4 weeks and 3 more. Started Nov 2015; status: completed.
02
Drugs
evobrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02537028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537028.